Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics presented data from their bioMUSE natural history study at the 35th International Symposium on the Autonomic Nervous System. The presentation focused on tracking Multiple System Atrophy (MSA) progression using advanced neuroimaging techniques. The study introduced the MSA Atrophy Index (MSA-AI), a composite marker derived from specific brain regions to assess disease progression.
Using machine learning tools and state-of-the-art technology beyond traditional MRI methods, researchers observed significant brain volume reductions over 12 months that correlated with clinical worsening. These methods aim to enhance understanding of MSA progression and support the evaluation of disease-modifying therapies.
Alterity Therapeutics ha presentato dati dal loro studio sulla storia naturale bioMUSE al 35° Simposio Internazionale sul Sistema Nervoso Autonomo. La presentazione si è concentrata sul monitoraggio della progressione della Atrofia Multisistemica (MSA) utilizzando tecniche avanzate di neuroimaging. Lo studio ha introdotto l'Indice di Atrofia MSA (MSA-AI), un marker composito derivato da specifiche aree cerebrali per valutare la progressione della malattia.
Utilizzando strumenti di apprendimento automatico e tecnologie all'avanguardia oltre ai metodi di risonanza magnetica tradizionali, i ricercatori hanno osservato significative riduzioni del volume cerebrale nel corso di 12 mesi che si sono correlate a un peggioramento clinico. Questi metodi mirano a migliorare la comprensione della progressione della MSA e a supportare la valutazione delle terapie modificanti la malattia.
Alterity Therapeutics presentó datos de su estudio de historia natural bioMUSE en el 35° Simposio Internacional sobre el Sistema Nervioso Autónomo. La presentación se centró en el seguimiento de la progresión de la Atrofia Multisistémica (MSA) utilizando técnicas avanzadas de neuroimagen. El estudio introdujo el Índice de Atrofia MSA (MSA-AI), un marcador compuesto derivado de regiones específicas del cerebro para evaluar la progresión de la enfermedad.
Mediante herramientas de aprendizaje automático y tecnología de punta más allá de los métodos de resonancia magnética tradicionales, los investigadores observaron reducciones significativas en el volumen cerebral durante 12 meses que se correlacionaron con el empeoramiento clínico. Estos métodos tienen como objetivo mejorar la comprensión de la progresión de la MSA y apoyar la evaluación de terapias modificadoras de la enfermedad.
Alterity Therapeutics는 제 35회 자율 신경계 국제 심포지엄에서 bioMUSE 자연사 연구의 데이터를 발표했습니다. 발표는 고급 신경 이미징 기법을 사용하여 다계통 위축증 (MSA)의 진행 상황을 추적하는 데 초점을 맞추었습니다. 이 연구에서는 질병 진행 상황을 평가하기 위해 특정 뇌 영역에서 파생된 복합 지표인 MSA 위축 지수 (MSA-AI)를 도입했습니다.
기계 학습 도구와 전통적인 MRI 방법을 넘어서는 최첨단 기술을 사용하여 연구자들은 12개월 동안 임상 악화와 상관관계를 가진 뇌 용적의 유의미한 감소를 관찰했습니다. 이러한 방법은 MSA 진행 상황에 대한 이해를 향상하고 질병 수정 치료 평가를 지원하는 데 목적이 있습니다.
Alterity Therapeutics a présenté des données issues de son étude sur l'histoire naturelle bioMUSE lors du 35e Symposium International sur le Système Nerveux Autonome. La présentation a porté sur le suivi de la progression de l'Atrophie Multi-Systémique (MSA) à l'aide de techniques avancées d'imagerie cérébrale. L'étude a introduit l'Indice d'Atrophie MSA (MSA-AI), un marqueur composite dérivé de régions cérébrales spécifiques pour évaluer la progression de la maladie.
En utilisant des outils d'apprentissage automatique et des technologies de pointe au-delà des méthodes d'IRM traditionnelles, les chercheurs ont observé des réductions significatives du volume cérébral sur 12 mois, corrélées à une aggravation clinique. Ces méthodes visent à améliorer la compréhension de la progression de la MSA et à soutenir l'évaluation des thérapies modifiant la maladie.
Alterity Therapeutics präsentierte Daten aus ihrer bioMUSE-Studie zur natürlichen Geschichte auf dem 35. Internationalen Symposium über das autonome Nervensystem. Die Präsentation konzentrierte sich auf die Verfolgung des Fortschreitens der Multisystematrophie (MSA) mithilfe fortschrittlicher Neuroimaging-Techniken. Die Studie führte den MSA Atrophie-Index (MSA-AI) ein, einen zusammengesetzten Marker, der aus spezifischen Hirnregionen abgeleitet wird, um den Krankheitsverlauf zu bewerten.
Durch den Einsatz von Werkzeugen des maschinellen Lernens und modernster Technologie, die über traditionelle MRT-Methoden hinausgeht, beobachteten die Forscher signifikante Reduzierungen des Hirnvolumens über 12 Monate, die mit einer klinischen Verschlechterung korrelierten. Diese Methoden zielen darauf ab, das Verständnis der MSA-Progression zu verbessern und die Bewertung von krankheitsmodifizierenden Therapien zu unterstützen.
- Development of new MSA Atrophy Index (MSA-AI) as a potential biomarker for disease progression
- Successful correlation between brain volume reduction and clinical disease progression
- Implementation of advanced neuroimaging methods in Phase 2 clinical trials
- None.
Insights
The presentation of bioMUSE study data introduces a novel neuroimaging biomarker called the MSA Atrophy Index (MSA-AI), which represents incremental progress in tracking Multiple System Atrophy progression. While scientifically interesting, this development primarily represents a research tool rather than a direct value driver for investors.
The correlation between brain volume reduction and clinical disease progression validates the company's imaging approach in their ongoing Phase 2 trials. However, this is more of a supporting technical achievement rather than a critical milestone that would significantly impact the company's valuation or market position.
For a micro-cap company with
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International Symposium on the Autonomic Nervous System.
“The data presented highlights our work to better understand not only how multiple system atrophy (MSA) initially presents, but also how it progresses over time,” said David Stamler, M.D., Chief Executive Officer of Alterity. “The presentation describes the use of state-of-the-art technology that goes beyond traditional MRI methods to track the change in volume in specific regions of the brain affected in patients with MSA. Importantly, we observed that significant reductions in brain volume over 12 months correlated with clinical worsening of the disease. The results underscore the importance of utilizing advanced neuroimaging and analytical methods in evaluating MSA which we have implemented in our Phase 2 clinical trials.”
The platform presentation entitled, “The MSA Atrophy Index: A Marker of Clinical Progression in Multiple System Atrophy”, was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center.
While previous MRI studies have reported brain volume reductions in regions implicated in MSA, tracking these changes reliably has been challenging. In this study, machine learning tools were used to precisely define the neuroanatomy and a specific brain atrophy measure was designed to track disease progression in MSA patients over one year. The results were then correlated with clinical measures of disease progression. The poster introduces the MSA Atrophy Index (MSA-AI), a composite atrophy marker derived from the lentiform nucleus (LN, putamen and globus pallidus) and olivopontocerebellar (OPC, cerebellum and brainstem) regions, as a potential biomarker for assessing MSA progression. These methods can enhance the understanding of MSA progression and provide support for using brain atrophy markers for the evaluation of disease-modifying therapies.
About bioMUSE
Biomarkers of progression in Multiple System Atrophy (bioMUSE) is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, M.D., M.S., Professor of Neurology and Principal Investigator. Natural history studies are important for characterizing disease progression in selected patient populations. The study has provided rich data for optimizing the design of Alterity’s randomized ATH434-201 Phase 2 clinical trial and enrolled approximately 20 individuals with clinically probable or clinically established MSA. BioMUSE continues to provide vital information on early stage MSA patients, informs the selection of biomarkers suitable to evaluate target engagement and preliminary efficacy, and delivers clinical data to characterize disease progression in a patient population that mirrors those currently enrolling in the Phase 2 clinical trial.
About Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. It is a rapidly progressive disease and causes profound disability. MSA is a Parkinsonian disorder characterized by a variable combination of slowed movement and/or rigidity, autonomic instability that affects involuntary functions such as blood pressure maintenance and bladder control, and impaired balance and/or coordination that predisposes to falls. A pathological hallmark of MSA is the accumulation of the protein α-synuclein within glia, the support cells of the central nervous system, and neuron loss in multiple brain regions. MSA affects at least 15,000 individuals in the U.S., and while some of the symptoms of MSA can be treated with medications, currently there are no drugs that are able to slow disease progression and there is no cure.1
1Multiple System Atrophy | National Institute of Neurological Disorders and Stroke (nih.gov)
About Parkinson’s Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and causes unintended or uncontrollable movements of the body along with neuropsychiatric and other nonmotor features. The precise cause of PD is unknown, but some cases are hereditary while others are thought to occur from a combination of genetics and environmental factors that trigger the disease. In PD, brain cells become damaged or die in the substantia nigra, the part of the brain that produces dopamine--a chemical needed to produce smooth, purposeful movement. The cardinal symptoms of PD are tremors, rigidity, slowing of movements, and later in disease, impaired balance. Other symptoms may include difficulty swallowing, chewing, or speaking; emotional changes; urinary problems or constipation; dementia or other cognitive problems; fatigue; and problems sleeping.2 Nearly one million people in the U.S. and more than 10 million people worldwide are living with PD. Approximately 60,000 Americans are diagnosed with PD each year.3
2National Institute of Health: Neurological Disorders and Stroke, Parkinson's Disease Information Page; 3Parkinson’s Foundation
About Alzheimer’s Disease
Alzheimer's disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die. Alzheimer's disease is the most common cause of dementia — a continuous decline in thinking, behavioral, and social skills that affects a person's ability to function independently. Approximately 5.8 million people in the United States age 65 and older live with Alzheimer's disease. Of those,
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ
What is the MSA Atrophy Index (MSA-AI) presented by Alterity Therapeutics (ATHE)?
What were the key findings of Alterity Therapeutics' (ATHE) bioMUSE study presentation in 2024?
How is Alterity Therapeutics (ATHE) tracking Multiple System Atrophy progression?
